Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 8, 2009, Pages 874-881

  Siegel, Corey A ^a,b   Marden, Sadie M ^b   Persing, Sarah M ^b   Larson, Robin J ^b   Sands, Bruce E ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROHN DISEASE; DRUG EXPOSURE; EMBASE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; MEDLINE; META ANALYSIS; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ADULT; AGED; ANIMALS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67949112671     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.01.004     Document Type: Article

References (50)

1. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5 (2007) 1424-1429
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
4. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
5. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
6. Sandborn W.J., and Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5 (1999) 119-133
7. Lichtenstein G.R., Cohen R.D., Feagan B.G., et al. Safety of infliximab and other Crohn's disease therapies-Treat (TM) registry data with nearly 20,000 patient-years of follow-up. Gastroenterology 132 (2007) A178
8. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
9. Loftus Jr. E.V., Tremaine W.J., Habermann T.M., et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95 (2000) 2308-2312
10. Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
11. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
12. SEER. Surveillance, Epidemiology, and End Results Database. http://seer.cancer.gov/ Accessed on November 6, 2007
13. Colombel J.F., Rutgeerts P., Sandborn W.J., et al. Adalimumab safety in Crohn's disease patients: open-label maintenance following the GAIN and CHARM trials. Am J Gastroenterol 102 (2007) S496-S497
14. Mantzaris G.J., Ployzou P., Karagiannidis A., et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease (CD). Gastroenterology 126 (2004) A54
15. Lemann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
16. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
17. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
18. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007) 1232-1239
19. Seiderer J., Goke B., and Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients: a retrospective cohort study in 100 patients of a German University Hospital. Digestion 70 (2004) 3-9
20. Ardizzone S., Maconi G., Colombo E., et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 10 (2004) 91-96
21. Carbone J., Gonzalez-Lara V., Sarmiento E., et al. Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann N Y Acad Sci 1107 (2007) 346-355
22. Choi K.D., Song H.J., Kim J.S., et al. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. Korean Journal of Gastroenterology/Taehan Sohwagi Hakhoe Chi 46 (2005) 48-55
23. Hyder S.A., Travis S.P., Jewell D.P., et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 49 (2006) 1837-1841
24. Talbot C., Sagar P.M., Johnston M.J., et al. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Disease 7 (2005) 164-168
25. Kinney T., Rawlins M., Kozarek R., et al. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98 (2003) 608-612
26. Cochrane handbook for systematic reviews of interventions. http://www.cochrane-handbook.org/ Accessed June 25, 2008
27. Colombel J.F., Schreiber S., Hanauer S.B., et al. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: results from precise 3 and 4. Gastroenterology 132 (2007) A503
28. Sands B.E., Blank M.A., Patel K., et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2 (2004) 912-920
29. Lemann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
30. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007) 1232-1239
31. Schroder O., Blumenstein I., and Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol 18 (2006) 11-16
32. Biancone L., Orlando A., Kohn A., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233
33. Doumit J., Brzezinski A., Lashner B., et al. Comparison of safety and mortality of infliximab therapy to immunomodulator therapy in Crohn's disease: a cohort study. Am J Gastroenterol 100 (2005) S306
34. Cohen R.D. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 7 Suppl 1 (2001) S17-S22
35. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
36. Peyrin-Biroulet L., Laclotte C., and Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 25 (2007) 675-680
37. Rodrigo L., Perez-Pariente J.M., Fuentes D., et al. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease. [erratum appears in Rev Esp Enferm Dig 2004;96:737]. Revista Espanola de Enfermedades Digestivas 96 (2004) 548-558
38. Schroder O., Blumenstein I., Schulte-Bockholt A., et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 19 (2004) 295-301
39. Seiderer J., Goke B., and Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients: a retrospective cohort study in 100 patients of a German University Hospital. Digestion 70 (2004) 3-9
40. Pacault V., Hriz F.B., Gornet J.M., et al. Long term follow up of Crohn's disease patients treated with infliximab using an episodic strategy. Gastroenterology 130 (2006) A655
41. Peloquin J.M., Pardi D.S., Sandborn W.J., et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 103 (2008) 2015-2022
42. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
43. Beaugerie L., Carrat F., Bouvier A.M., et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort. Gastroenterology 134 (2008) A-116
44. Desmond A.N., O'Regan K.N., Curran C., et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gastroenterology 134 (2008) A-20
45. Brenner D.J., and Hall E.J. Computed tomography: an increasing source of radiation exposure. N Engl J Med 357 (2007) 2277-2284
46. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6 (2008) 644-653
47. Katanoda K., and Yako-Suketomo H. Comparison of time trends in Hodgkin and non-Hodgkin lymphoma incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents. Vol IV-VIII. Jpn J Clin Oncol 38 (2008) 391-393
48. Johnson F.R., Ozdemir S., Mansfield C., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133 (2007) 769-779
49. Sands B.E., Siegel C.A., Johnson F.R., et al. Gastroenterologists' tolerance for Crohn's disease treatment risks (October 29, 2007), Presented at the United European Gastroenterology Week, Paris, France
50. Johnson F.R., Ozdemir S., Mansfield C., et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients?. Risk Anal 29 (2009) 121-136